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Background: Lung cancer remains a leading cause of cancer-
related mortality in North America. Despite potentially curative
resection, non-small cell lung cancer (NSCLC) patients remain at
high risk of relapse and death, with a 5-year survival rate of less than
67%. Several randomized trials now confirm a survival benefit with
adjuvant platinum-based chemotherapy seen in the NSCLC Collab-
orative Group meta-analysis, including the International Adjuvant
Lung Trial, National Cancer Institute of Canada BR.10, and Adju-
vant Navelbine International Trialist Association (ANITA) trials,
with absolute improvements in 4- and 5-year survival rates of 4% to
15%. This study examines whether referral patterns for adjuvant
therapy in NSCLC have changed since the presentation of confir-
matory trials.
Methods: Retrospective chart review was undertaken at a major
tertiary care center, identifying patients with completely resected
stages I–IIIA NSCLC from May 2003 to May 2005.
Results: A total of 204 patients were identified (59 IA, 77 IB, 8 IIA,
41 IIB, and 19 IIIA). Institutional policy before May of 2003 was
not to administer adjuvant therapy outside a clinical trial. After
presentation of the International Adjuvant Lung Trial in May 2003,
31% (36/115) of patients with completely resected NSCLC from
May 2003 to May 2004 were referred for adjuvant chemotherapy.
After presentation of the BR.10 and Cancer and Leukemia Group B
9633 results in June 2004, 63% (56/89) were referred between June
2004 and May 2005. Reasons for not referring to a medical oncol-
ogist included stage IA disease, surgeon thought adjuvant therapy
inappropriate, patient declined, comorbidities, postoperative compli-
cations, and advanced age. Of 92 patients referred to medical
oncology, 42 (46%) received adjuvant chemotherapy. Reasons for
not prescribing adjuvant chemotherapy included patient refusal
(50%), comorbidities (14%), stage IA (10%), and advanced age
(4%). Vinorelbine/cisplatin was the regimen most commonly used
(67%).
Conclusions: The presentation of positive adjuvant therapy trials in
NSCLC has changed clinical practice substantially, doubling the
number of patients with completely resected NSCLC referred for
adjuvant chemotherapy since May 2004 (31% versus 63%). Al-
though new evidence to support adjuvant chemotherapy in lung
cancer is being disseminated to and accepted by physicians, more
patient education and decision support may be required to increase
uptake of adjuvant therapy in the early stage NSCLC population.
(J Thorac Oncol. 2007;2: 39–43)
Lung cancer is the leading cause of cancer-related mortalityin North America, with non-small cell lung cancer
(NSCLC) accounting for 80% of cases.1 Complete resection
still offers the best chance of cure for the one third of patients
who present with early-stage disease. However, despite cur-
ative resection, these patients are still at high risk of recur-
rence and ultimately death from lung cancer. Mountain and
colleagues2 found that 5-year survival rates after resection
were less than 67% for patients with pathologic stage I
disease and as low as 23% for those with stage IIIA. Given
that distant metastasis is the most common site of relapse for
early stage disease, adjuvant chemotherapy for NSCLC has
been an area of intense study over the past 40 years.
In 1995, the NSCLC Collaborative Group conducted a
meta-analysis of 14 randomized trials with 4357 patients,
comparing surgical resection alone to resection followed by
adjuvant chemotherapy.3 Patients receiving platinum-based
chemotherapy had a trend toward overall reduction in mor-
tality with a hazard ratio of 0.87 (p  0.08), translating to an
absolute reduction in mortality of 5% at 5 years. In contrast,
patients receiving adjuvant chemotherapy with alkylating
agents had an increased mortality rate compared to those
treated with surgery alone. Thus, selection of optimal che-
motherapy regimens for further adjuvant studies has been of
key importance.
The results of the International Adjuvant Lung Trial
(IALT), the largest randomized trial to show a survival
benefit from adjuvant chemotherapy in NSCLC, were first
presented in May 2003.4 A total of 1867 patients with
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completely resected stage I–IIIA NSCLC were randomly
assigned to surgery alone or surgery followed by three to four
cycles of adjuvant chemotherapy with a cisplatin-containing
doublet. Overall survival was significantly better among pa-
tients receiving chemotherapy, with a hazard ratio of 0.86
(p  0.03), and an absolute survival benefit of 4.1% at 5
years. This magnitude of benefit is similar to that seen in the
NSCLC Collaborative Group meta-analysis. However, three
additional randomized trials of adjuvant chemotherapy con-
ducted at about the same time failed to demonstrate a survival
benefit. These included the Eastern Cooperative Oncology
Group (ECOG) trial5 of adjuvant radiation with or without
etoposide and cisplatin, the Big Lung Trial6 that allowed a
variety of platinum-based chemotherapy regimens (mostly
second generation), and the Adjuvant Lung Project Italy
trial7 that employed mitomycin, vindesine, and cisplatin. A
number of reasons have been cited for the variable results
among the trials including patient heterogeneity, ineffective
chemotherapy regimens, poor compliance, inadequate sample
size, and potential interaction with radiotherapy. However,
given these contradictory results and the modest survival
benefit seen in IALT, surgeons, physicians, and patients
themselves remained unconvinced of the benefits of adjuvant
chemotherapy.8,9
Recently, two of three adjuvant trials of third-genera-
tion platinum-based combinations have demonstrated a clear
survival benefit in patients receiving adjuvant chemotherapy.
The National Cancer Institute of Canada Clinical Trials
Group (NCIC CTG) JBR.10 study included patients with
completely resected stage IB–IIB NSCLC and patients were
randomized postoperatively to four cycles of adjuvant vi-
norelbine/cisplatin or observation alone.10 This study demon-
strated a significant reduction in mortality, with a hazard ratio
of 0.69 (p 0.011), an absolute 5-year survival improvement
of 15%, and a median prolongation in survival of 21 months.
The Cancer and Leukemia Group B (CALGB) 9633 trial
included only patients with completely resected stage IB
NSCLC, and patients were randomized to receive four cycles
of adjuvant paclitaxel/carboplatin or observation without che-
motherapy.11 This study was closed prematurely after an
interim analysis demonstrated a reduction in mortality (haz-
ard ratio of 0.62, p  0.028), with a projected absolute
survival improvement of 12% at 4 years. However, with
longer follow-up, this survival benefit lost statistical signifi-
cance, although disease-free survival (hazard ratio of 0.74,
p  0.03), and 2- and 3-year survival rates remained superior
in the adjuvant chemotherapy arm, and subset analysis re-
vealed that patients with tumors 4 cm in size still appeared
to derive a benefit from adjuvant paclitaxel/carboplatin. This
change in results might be explained by the study’s small
sample size, and a larger sample size may be required to
detect a difference in survival after adjuvant chemotherapy in
patients with completely resected stage IB NSCLC.12 Most
recently, the ANITA-1 trial, reported in May 2005, confirmed
the benefit of adjuvant vinorelbine/cisplatin in 840 patients
with completely resected stage I–IIIA NSCLC, with an ab-
solute improvement in survival of 8% at 5 years (p 
0.013).13
The Lung Adjuvant Cisplatin Evaluation (LACE) Col-
laborative group has recently presented a meta-analysis of
five large randomized trials completed after the 1995 NSCLC
Collaborative Group Meta-analysis.14 It included individual
data on 4584 NSCLC patients randomized to receive adjuvant
cisplatin-based chemotherapy or surgery alone, with or with-
out postoperative radiotherapy, and included the Adjuvant
Lung Project Italy, ANITA, IALT, Big Lung Trial, and NCIC
Clinical Trials Group (NCIC CTG) JBR.10. Results revealed
cisplatin-based adjuvant chemotherapy improved overall
(hazard ratio of 0.84, p  0.001), and disease-free survival
with an absolute 5-year survival benefit of 5.5%, similar to
that seen in the NSCLC Collaborative Group Meta-analysis.
Cisplatin combined with vinorelbine appeared to be the most
efficacious combination; however, this was confounded by
the higher cisplatin protocol dose used with vinorelbine.
Thus, adjuvant chemotherapy for completely resected
early-stage NSCLC has become a new standard, with evi-
dence to support platinum-based combination treatment in
stage IB–IIIA resected NSCLC. But has this evidence trans-
lated into clinical practice? This study seeks to evaluate
whether referral patterns for adjuvant chemotherapy in com-
pletely resected NSCLC patients have changed with the
presentation of recent positive randomized trials and also to
identify potential barriers to patients being referred for con-
sideration of adjuvant chemotherapy and/or subsequently
receiving chemotherapy treatment.
PATIENTS AND METHODS
A retrospective chart review was conducted at a tertiary
care center (University Health Network/Princess Margaret
Hospital) in Toronto. Patients who had undergone complete
resection of pathologic stage I–IIIA NSCLC from May 2003
to May 2005 were included. Before May 2003, adjuvant
chemotherapy was not routinely offered to this population
outside a clinical trial. Patients were identified using an
institutional cancer registry that was cross-referenced with
operating room lists and a pathology database for accuracy.
Patients receiving neoadjuvant chemotherapy were excluded.
Data were collected for two specific time periods: May 2003
until May 2004, the first year after presentation of the IALT
TABLE 1. Distribution of Patients by Age, Gender, and
Stage
May 2003–May 2004
(n  115)
June 2004–May 2005
(n  89)
Total
(N  204)
Gender
Male 56 46 102
Female 59 43 102
Age, y 70.4 69.0 69.8
Stage
IA 34 25 59
IB 39 38 77
IIA 5 3 8
IIB 27 14 41
IIIA 10 9 19
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results, and June 2004 to May 2005, the first year after
presentation of the results of the NCIC CTG and CALGB
adjuvant trials. Institutional ethics approval was received for
the conduct of this study.
Rates of referral for patients during these two time
periods are summarized, as are patient and disease charac-
teristics including tumor stage and whether chemotherapy
was given. Wherever possible, the reason for not referring
patients or not prescribing chemotherapy was recorded and
summarized.
RESULTS
A total of 204 patients who had complete resection of
early-stage NSCLC between May 2003 and May 2005 were
identified (Table 1).
Institutional policy before May 2003 was not to admin-
ister adjuvant therapy outside a clinical trial. After presenta-
tion of the IALT trial in May 2003, 31% (36/115) of patients
who underwent complete resection of NSCLC from May
2003 to May 2004 were referred for adjuvant chemotherapy.
After presentation of JBR.10 and CALGB 9633 results at the
American Society of Clinical Oncology 2004 annual meeting
in May 2004, 63% (56/89) were referred from June 2004 toMay
2005 (Table 2). If the stage IA patients are excluded, referral
rates reach 80% for the stage IB–IIIA subgroups (Figure 1).
Reasons identified for not referring a patient to a
medical oncologist for consideration of adjuvant chemother-
apy included stage IA disease (37%), patient declined (18%),
surgeon thought adjuvant therapy inappropriate (15%), sig-
nificant comorbidities (10%), postoperative complications
(5%), disease progression (3%), and advanced age (2%)
(Table 3).
Of 92 patients referred to a medical oncologist, only 42
(46%) received adjuvant chemotherapy (Figure 2). This rep-
FIGURE 1. Patterns of referral for adjuvant chemotherapy in resected stage IA–IIIA (left) and stage IB–IIIA (right) NSCLC.
TABLE 2. Patterns of Referral to Medical Oncology by Stage and Time Period
Stage
May 2003–May 2004 June 2004–May 2005
Total
No.
No.
Referred
%
Referred
No. Treated
with Chemotherapy
Total
No.
No.
Referred
%
Referred
No. Treated
with Chemotherapy
IA 34 1 3 0 25 5 20 0
IB 39 13 33 4 38 30 79 18
IIA 5 3 60 0 3 1 33 1
IIB 27 12 44 6 14 12 86 7
IIIA 10 7 70 2 9 8 89 4
Total 115 36 31 12 89 56 63 30
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resents one third (33%) of patients referred post-IALT, and
54% post-JBR.10 and CALGB 9633. Reasons for not pre-
scribing adjuvant chemotherapy included patient refusal
(50%), comorbidities (14%), stage IA disease (10%), disease
progression (6%), advanced age (6%), and unknown (14%)
(Table 4). Vinorelbine/cisplatin was the regimen most com-
monly employed (for 67% of patients) (Table 5).
DISCUSSION
Evidence supporting the survival benefit of adjuvant
platinum-based chemotherapy seen in the NSCLC Collabo-
rative Group meta-analysis has been accumulating since May
2003. After the presentation of the IALT that year, 31% of
completely resected NSCLC patients at a major academic
center were being referred for adjuvant chemotherapy,
whereas before May 2003, almost no patients were being
referred outside of a clinical trial. This number doubled to
63% following the presentation of CALGB 9633 and NCIC
CTG JBR.10 at the American Society of Clinical Oncology
2004 annual meeting, clearly illustrating the assimilation of
evidence into clinical practice on the part of thoracic sur-
geons. Furthermore, once referred to a medical oncologist,
the number of patients who received chemotherapy increased
from 33% post-IALT to 54% after the CALGB 9633 and
NCIC JBR.10 presentations. This indicates clinical uptake of
evidence by medical oncologists and patients as well.
The most common reason for patients not to be referred
to a medical oncologist was the presence of stage IA NSCLC,
which is appropriate in view of the lack of evidence to
support adjuvant chemotherapy in stage IA patients outside
Japan. This was also the second most common reason for
patients not to receive chemotherapy once referred to a
medical oncologist. There is a paucity of evidence surround-
ing the role of adjuvant platinum-based chemotherapy in
stage IA disease, as these patients were excluded from the
CALGB 9633, NCIC CTG JBR.10, and ANITA trials. IALT
remains the only large positive randomized trial to have
included this subgroup of patients, and although no subgroup
analysis was conducted for stage IA patients specifically, the
TABLE 3. Reasons Identified from Surgeons for Not
Referring Patients to Medical Oncology
Rank Reason
% of Patients
(N  112)
1 Stage IA disease 37
2 Patient declined 18
3 Surgeon thought no role 15
4 Comorbid disease 10
5 Complicated postoperative course 5
6 Disease progression/death 3
7 Advanced age 2
8 Unknown 16
FIGURE 2. Disposition of patients re-
ferred to medical oncology.
TABLE 4. Reasons Identified for Not Receiving
Chemotherapy Once Referred to Medical Oncology
Rank Reason Identified
% of Patients
(N  50)
1 Patient declined 50
2 Comorbid disease 14
3 Stage IA disease/MO thought no role 10
4 Disease progression 6
5 Advanced age 6
6 Unknown 14
TABLE 5. Chemotherapy Regimens Prescribed
Rank Chemotherapy Regimen
No. of Patients
(N  42)
1 Vinorelbine/cisplatin 28
2. Etoposide/cisplatin 4
3 Paclitaxel/carboplatin 4
4 Gemcitabine/cisplatin 1
5 Unknown 5
Kassam et al. Journal of Thoracic Oncology • Volume 2, Number 1, January 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer42
stage I group overall did benefit from chemotherapy. How-
ever, the results of the LACE meta-analysis suggest a poten-
tial harmful effect of adjuvant cisplatin-based chemotherapy
in this subset of patients. With regards to stage IB disease,
subset analyses from the ANITA and JBR.10 trials suggest
that this group may not benefit from adjuvant vinorelbine/
cisplatin. The LACE meta-analysis also failed to find a
statistically significant improvement in the IB subset, based
on published studies to date. Of note, the CALGB trial did not
contribute individual patient data to the LACE meta-analysis;
thus, questions remain about the value of adjuvant chemo-
therapy in completely resected stage IB NSCLC. It will be
interesting to examine how this latest update affects the
adjuvant therapy referral and treatment patterns for patients
with IB NSCLC. Finally, a meta-analysis of adjuvant oral
UFT did find a significant absolute survival advantage of 5%
in stage I patients (hazard ratio of 0.74), with the majority of
benefit derived in patients with stage IB NSCLC.15 Further
studies are clearly needed to elucidate the role of chemother-
apy in the stage I subgroup and to evaluate the role of UFT
in non-Japanese patients.
On examination of referral patterns by stage, propor-
tionately more patients were referred for adjuvant chemother-
apy with increasing stage. It appears that patients perceived to
be at higher risk of recurrence, and therefore more likely to
benefit from adjuvant chemotherapy, are being referred for
treatment. This perception of increasing benefit with increas-
ing stage is supported by IALT, which found stage III or N2
patients benefited most from adjuvant chemotherapy, as well
as the ANITA and JBR.10 trials, and further confirmed by the
LACE meta-analysis. Efforts should clearly be made to
increase uptake of adjuvant chemotherapy in all patients with
completely resected stage II–IIIA NSCLC, with possible
consideration of chemotherapy for patients with stage IB
disease and potentially worse prognostic features, e.g., large
tumors greater than 4 cm in size, although benefit in this
subset remains to be confirmed.
Despite being referred to a medical oncologist, 27% of
patients decline chemotherapy even when it is recommended to
them. This represents approximately half of the patients who did
not proceed with treatment. This suggests that better patient
education and decision support should be developed to explain
and promote the value of adjuvant chemotherapy and to improve
outcomes in this patient population. However, it is encouraging
that chemotherapy uptake has increased substantially (from zero
to 33% and eventually 54%) after presentation of the favorable
results in the recent adjuvant trials.
As expected, vinorelbine plus cisplatin was the chemo-
therapy regimen most commonly prescribed at this institu-
tion, given that this was a center participating in the NCIC
CTG JBR.10 study that used this combination. The LACE
meta-analysis suggested that this combination may be the
most efficacious cisplatin doublets; however, again this may
have been confounded by higher cisplatin protocol doses
when combined with vinorelbine. Other third-generation dou-
blets were used occasionally, indicating oncologist support
for novel chemotherapy combinations as optimal adjuvant
treatment.
These data are encouraging and demonstrate rapid up-
take of new evidence on adjuvant chemotherapy in NSCLC
into clinical practice at a major academic center. To assess
whether these findings are generalizable to the community, a
similar study comparing referral patterns in academic and
community centers is ongoing.
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